Feature | April 08, 2011

Drug-Eluting Stents Improve Outcomes in Saphenous Vein Graft Lesions

In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led to a lower combined rate of death, heart attack and repeat revascularization. The research findings were presented this week at the American College of Cardiology’s 60th Annual Scientific Session.

While saphenous vein grafts (SVGs) have been used extensively in coronary artery bypass graft (CABG) surgery, these conduits often develop atherosclerotic disease that results in vessel narrowing or closure. Conducting a second CABG surgery to fix the graft is possible but can result in higher mortality and morbidity rates than the first operation. Performing angioplasty with a stent is an alternative to repeat CABG surgery, and research is still being conducted to optimize this procedure.

“DES have proven superior to BMS in all coronary artery lesion subsets examined, but their performance has been insufficiently evaluated in SVG lesions,” said Julinda Mehilli, M.D., director of clinical research and data coordinating in the Intracoronary Stenting and Antithrombosis Research (ISAR) Center at the German Heart Center Munich, Germany. “The only two very small randomized trials comparing DES with BMS in SVG lesions provided conflicting results. Thus, the aim of the ISAR-CABG trial was to investigate this question in a larger population sufficiently powered to provide information on clinical endpoints.”

For the study, German researchers enrolled 610 patients who had previously undergone CABG surgery. All study patients had subsequently developed at least one lesion in their saphenous vein graft and were randomized to receive either a DES (n = 303) or a BMS (n = 307) in the study angioplasty procedure.

The study’s primary endpoint was a composite of major adverse cardiac events, including death, heart attack, and target-lesion revascularization (TLR) at the one-year follow-up point. The secondary endpoints were the individual rates of death, heart attack, Academic Research Consortium (ARC) definite stent thrombosis and the need for TLR over one year.

The researchers found that the incidence of major adverse cardiac events was reduced by 35 percent in the DES cohort compared to the BMS group. Specifically, 16.5 percent of patients in the DES group experienced the primary endpoint compared with 22.1 percent of patients in the BMS group (hazard ratio [HR] 0.65; 95 percent confidence interval [CI] 0.45 – 0.96; p = 0.028). The reduction in the DES group was primarily due to a significantly lower rate of TLR, which occurred in 7.2 percent of patients in the DES group and in 12.9 percent of patients in the BMS group (HR 0.52; 95 percent CI 0.3 – 0.9; p = 0.020).

The research team found no significant differences in the individual rates of death or heart attack. Additionally, only one patient in the DES cohort experienced ARC-definite stent thrombosis. None of the patients in the BMS group experienced this outcome.

“Saphenous vein graft lesions remain a challenging disease subset for angioplasty. The ISAR-CABG trial, however, demonstrates that DES can safely be used to reduce adverse events in this high-risk subset of patients,” Mehilli said.

The study was funded by the German Heart Center Munich and by Cordis. Mehilli had no disclosures to report.

For more information: www.cardiosource.org

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init